On May 18, 2023 BeyondSpring Inc. (NASDAQ: BYSI) ("BeyondSpring" or the "Company"), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs, reported that the Company and Memorial Sloan Kettering Cancer Center (MSK) will present a poster at the 2023 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place on June 2 through 6 in Chicago, IL (Press release, BeyondSpring Pharmaceuticals, MAY 18, 2023, View Source;utm_medium=rss&utm_campaign=beyondspring-and-leading-cancer-center-to-present-poster-at-2023-asco-annual-meeting [SID1234631908]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster, titled, "Plinabulin to shorten neutropenia and improve quality of life peri-autologous hematopoietic cell transplant," will be presented by Dr. Gunjan Shah, MD, MS, Assistant Attending Physician at MSKCC and Principal Investigator of the BeyondSpring-MSKCC pilot trial evaluating Plinabulin in combination with pegfilgrastim in multiple myeloma patients who undergo an autologous hematopoietic cell transplant (AHCT).
Additional presentation details are as follows:
Poster Session Date / Time: Monday, June 5, 2023, at 9 a.m. to 12 p.m. ET
Location: McCormick Place Convention Center, Hall A
Track: Hematologic Malignancies
Abstract / Poster Board No.: 8023 / 15